Close Navigation
About ArixStrategy
OverviewInvestment caseNewsResultsDocumentsEventsCalendarAnalystsStock infoContact
AboutStrategyTeamPortfolioInsightsMediaContact
Investors
AboutStrategyTeamPortfolioInsightsMediaContact
Investors
Overlay

Harpoon Presents Interim Data from Ongoing Dose Escalation Portion of T Cell Engager HPN328 Clinical Trial at 2022 ASCO Annual Meeting

26th May 2022

Portfolio

This post references, or is about Harpoon. Find out more by clicking below

San Francisco, USA

Useful Tools

Download, print or share this article

Print Print Article Email Email Article
Print Save Article
Share Article
TwitterTwitterLinkedInLinkedInFacebookFacebook

Arix Bioscience

About Arix

The Team

Portfolio

Insights

News & Events

Contact

Investor Relations

Results Centre

Financial Calendar

Regulatory News

Document Library

Analysts & Advisors

Shareholder Information

Meta

Privacy Policy

Terms of use

Cookie Policy

Stay up to date

Sign up to receive regulatory news and results

Subscribe
Arix Bioscience
linkedintwitter

Arix Bioscience plc, registered in England and Wales with company number 09777975

Registered office: Duke Street House, 50 Duke Street, London, W1K 6JL, United Kingdom

Website by Ether